Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions
RYTM Stock Forecast
Rhythm Pharmaceuticals stock forecast is as follows: an average price target of $38.33 (represents a -22.75% downside from RYTM’s last price of $49.62) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
RYTM Price Target
The average price target for Rhythm Pharmaceuticals (RYTM) is $38.33 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $55.00 to $25.00. This represents a potential -22.75% downside from RYTM's last price of $49.62.
RYTM Analyst Ratings
According to 5 Wall Street analysts, Rhythm Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for RYTM stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Rhythm Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 25, 2024 | Alan Carr | Needham | $55.00 | $49.61 | 10.86% | 10.84% |
| Nov 10, 2022 | - | Goldman Sachs | $35.00 | $24.68 | 41.82% | -29.46% |
| Aug 07, 2022 | Corinne Jenkins | Goldman Sachs | $28.00 | $20.24 | 38.34% | -43.57% |
| Jul 12, 2022 | Corinne Jenkins | Goldman Sachs | $6.00 | $6.38 | -5.96% | -87.91% |
| Jun 17, 2022 | - | Needham | $25.00 | $3.90 | 541.03% | -49.62% |
| Jun 17, 2022 | Dae Gon Ha | Stifel Nicolaus | $25.00 | $3.90 | 541.03% | -49.62% |
The latest Rhythm Pharmaceuticals stock forecast, released on Jul 25, 2024 by Alan Carr from Needham, set a price target of $55.00, which represents a 10.86% increase from the stock price at the time of the forecast ($49.61), and a 10.84% increase from RYTM last price ($49.62).
Rhythm Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $55.00 | $55.00 |
| Last Closing Price | $49.62 | $49.62 | $49.62 |
| Upside/Downside | -100.00% | 10.84% | 10.84% |
In the current month, the average price target of Rhythm Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Rhythm Pharmaceuticals's last price of $49.62. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 25, 2024 | Needham | Buy | Buy | Hold |
| Feb 22, 2024 | Wells Fargo | Buy | Buy | Hold |
| Dec 19, 2023 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| Oct 10, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Aug 01, 2023 | Bank of America Securities | Neutral | Buy | Upgrade |
| Aug 07, 2022 | Goldman Sachs | Neutral | Buy | Upgrade |
| Aug 05, 2022 | Bank of America Securities | - | Neutral | Upgrade |
| Jul 12, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| Jun 17, 2022 | Needham | Buy | Buy | Hold |
| Feb 25, 2022 | Needham | Buy | Buy | Hold |
Rhythm Pharmaceuticals's last stock rating was published by Needham on Jul 25, 2024. The company gave RYTM a "Buy" rating, the same as its previous rate.
Rhythm Pharmaceuticals Financial Forecast
Rhythm Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $22.50M | $19.22M | $11.47M | $8.79M | $4.28M | - | $1.50M | $1.82M | $1.03M | $274.00K | $35.00K | - | - |
| Avg Forecast | $48.60M | $44.20M | $38.56M | $35.82M | $35.51M | $32.29M | $28.79M | $26.90M | $25.38M | $22.18M | $15.03M | $12.12M | $7.22M | $4.76M | $2.57M | $2.30M | $1.70M | $934.20K | $551.00K | $49.90M | $60.00K | $500.00K |
| High Forecast | $50.57M | $45.99M | $40.13M | $37.27M | $36.95M | $33.69M | $29.96M | $27.99M | $27.26M | $23.38M | $15.64M | $12.61M | $7.51M | $4.95M | $2.57M | $2.53M | $1.87M | $1.03M | $605.76K | $54.86M | $65.96K | $549.69K |
| Low Forecast | $45.67M | $41.53M | $36.24M | $33.66M | $33.37M | $30.08M | $27.05M | $25.27M | $23.88M | $21.00M | $14.12M | $11.39M | $6.78M | $4.47M | $2.57M | $2.10M | $1.55M | $851.78K | $502.39K | $45.50M | $54.71K | $455.89K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.01% | 1.28% | 0.95% | 1.22% | 0.90% | - | 0.65% | 1.07% | 1.10% | 0.50% | 0.00% | - | - |
Rhythm Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 7 analysts is $25.38M, with a low forecast of $23.88M, and a high forecast of $27.26M. RYTM's average Quarter revenue forecast represents a 12.78% increase compared to the company's last Quarter revenue of $22.50M (Sep 23).
Rhythm Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-40.65M | $-46.60M | $-49.12M | $-39.48M | $-38.27M | - | $-52.34M | $-42.54M | $-43.79M | $-40.09M | $65.96M | $-34.72M | $-33.65M |
| Avg Forecast | $-9.72M | $-8.84M | $-7.71M | $-7.16M | $-7.10M | $-6.46M | $-5.76M | $-5.38M | $-5.08M | $-4.44M | $-3.01M | $-2.42M | $-1.44M | $-952.26K | $-513.11K | $-460.04K | $-340.43K | $-51.08M | $-42.77M | $-9.98M | $-12.00K | $-35.39M |
| High Forecast | $-9.13M | $-8.31M | $-7.25M | $-6.73M | $-6.67M | $-6.02M | $-5.41M | $-5.05M | $-4.78M | $-4.20M | $-2.82M | $-2.28M | $-1.36M | $-894.75K | $-513.11K | $-419.45K | $-310.39K | $-40.87M | $-34.21M | $-9.10M | $-10.94K | $-28.31M |
| Low Forecast | $-10.11M | $-9.20M | $-8.03M | $-7.45M | $-7.39M | $-6.74M | $-5.99M | $-5.60M | $-5.45M | $-4.68M | $-3.13M | $-2.52M | $-1.50M | $-990.89K | $-513.11K | $-505.75K | $-374.26K | $-61.30M | $-51.32M | $-10.97M | $-13.19K | $-42.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | 9.16% | 15.51% | 20.26% | 27.35% | 40.19% | - | 113.78% | 124.96% | 0.86% | 0.94% | -6.61% | 2893.49% | 0.95% |
6 analysts predict RYTM's average Quarter EBITDA for Jun 21 to be $-42.77M, with a high of $-34.21M and a low of $-51.32M. This is -164.84% lower than Rhythm Pharmaceuticals's previous annual EBITDA (Mar 21) of $65.96M.
Rhythm Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | $-44.16M | $-46.70M | $-51.83M | $-42.88M | $-42.45M | - | $-52.84M | $-42.87M | $-35.11M | $-35.39M | $43.75M | $-34.90M | $-33.82M |
| Avg Forecast | $-46.37M | $-48.81M | $-54.30M | $-54.91M | $-47.28M | $-49.88M | $-43.25M | $-143.76M | $-43.05M | $-45.15M | $-48.67M | $-43.78M | $-49.35M | $-60.94M | $-57.44M | $-60.00M | $-54.05M | $-40.96M | $-37.75M | $43.75M | $-46.70M | $-35.09M |
| High Forecast | $-42.73M | $-44.98M | $-50.04M | $-50.60M | $-43.57M | $-35.10M | $-39.86M | $-132.47M | $-40.59M | $-37.43M | $-44.85M | $-40.34M | $-45.48M | $-56.15M | $-57.44M | $-53.12M | $-47.85M | $-32.77M | $-30.20M | $52.50M | $-41.35M | $-28.07M |
| Low Forecast | $-48.81M | $-51.38M | $-57.16M | $-57.81M | $-49.78M | $-75.74M | $-45.53M | $-151.34M | $-47.35M | $-57.62M | $-51.24M | $-46.08M | $-51.95M | $-64.15M | $-57.44M | $-67.75M | $-61.03M | $-49.15M | $-45.30M | $35.00M | $-52.74M | $-42.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.98% | 0.96% | 1.18% | 0.87% | 0.70% | - | 0.88% | 0.79% | 0.86% | 0.94% | 1.00% | 0.75% | 0.96% |
Rhythm Pharmaceuticals's average Quarter net income forecast for Jun 21 is $-37.75M, with a range of $-45.30M to $-30.20M. RYTM's average Quarter net income forecast represents a -186.28% decrease compared to the company's last Quarter net income of $43.75M (Mar 21).
Rhythm Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | $30.48M | $30.05M | $24.63M | $26.32M | $21.94M | - | $21.45M | $21.00M | $17.51M | $15.46M | $14.52M | $13.12M | $11.29M |
| Avg Forecast | $283.10M | $257.47M | $224.64M | $208.66M | $206.85M | $188.08M | $167.70M | $156.67M | $147.84M | $129.19M | $87.54M | $70.59M | $42.05M | $27.73M | $14.94M | $13.40M | $9.92M | $5.44M | $3.21M | $14.52M | $349.50K | $2.91M |
| High Forecast | $294.58M | $267.91M | $233.76M | $217.13M | $215.25M | $196.26M | $174.51M | $163.03M | $158.76M | $136.18M | $91.09M | $73.46M | $43.75M | $28.86M | $14.94M | $14.73M | $10.90M | $5.98M | $3.53M | $17.42M | $384.23K | $3.20M |
| Low Forecast | $266.00M | $241.92M | $211.08M | $196.06M | $194.36M | $175.23M | $157.57M | $147.21M | $139.10M | $122.31M | $82.26M | $66.33M | $39.51M | $26.06M | $14.94M | $12.22M | $9.04M | $4.96M | $2.93M | $11.61M | $318.67K | $2.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.24% | 0.34% | 0.35% | 0.63% | 0.79% | - | 1.60% | 2.12% | 3.22% | 4.82% | 1.00% | 37.54% | 3.88% |
Rhythm Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $147.84M, based on 7 Wall Street analysts, with a range of $139.10M to $158.76M. The forecast indicates a 385.12% rise compared to RYTM last annual SG&A of $30.48M (Sep 23).
Rhythm Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 4 | 7 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 4 | 5 | 6 | 3 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.76 | $-0.82 | $-0.91 | $-0.76 | $-0.83 | - | $-1.05 | $-0.85 | $-0.70 | $-0.70 | $0.92 | $-0.79 | $-0.77 |
| Avg Forecast | $-0.76 | $-0.80 | $-0.89 | $-0.90 | $-0.78 | $-0.82 | $-0.71 | $-2.36 | $-0.71 | $-0.74 | $-0.80 | $-0.72 | $-0.81 | $-1.00 | $-0.95 | $-1.01 | $-0.91 | $-0.81 | $-0.70 | $0.30 | $-0.79 | $-0.79 |
| High Forecast | $-0.70 | $-0.74 | $-0.82 | $-0.83 | $-0.71 | $-0.58 | $-0.65 | $-2.17 | $-0.67 | $-0.61 | $-0.74 | $-0.66 | $-0.75 | $-0.92 | $-0.95 | $-0.90 | $-0.81 | $-0.71 | $-0.62 | $0.34 | $-0.70 | $-0.70 |
| Low Forecast | $-0.80 | $-0.84 | $-0.94 | $-0.95 | $-0.82 | $-1.24 | $-0.75 | $-2.48 | $-0.78 | $-0.94 | $-0.84 | $-0.76 | $-0.85 | $-1.05 | $-0.95 | $-1.14 | $-1.03 | $-0.91 | $-0.79 | $0.26 | $-0.89 | $-0.89 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% | 1.27% | 0.94% | 0.83% | - | 1.04% | 0.93% | 0.87% | 0.99% | 3.08% | 1.00% | 0.97% |
According to 6 Wall Street analysts, Rhythm Pharmaceuticals's projected average Quarter EPS for Jun 21 is $-0.70, with a low estimate of $-0.79 and a high estimate of $-0.62. This represents a -176.49% decrease compared to RYTM previous annual EPS of $0.92 (Mar 21).
Rhythm Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| QURE | uniQure | $5.66 | $53.67 | 848.23% | Buy |
| PLRX | Pliant Therapeutics | $12.00 | $39.71 | 230.92% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| RLAY | Relay Therapeutics | $7.60 | $19.50 | 156.58% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| RCKT | Rocket Pharmaceuticals | $19.65 | $47.33 | 140.87% | Buy |
| BDTX | Black Diamond Therapeutics | $6.19 | $14.75 | 138.29% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| SLDB | Solid Biosciences | $7.93 | $17.50 | 120.68% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| VRDN | Viridian Therapeutics | $22.06 | $37.83 | 71.49% | Buy |
| AKRO | Akero Therapeutics | $27.34 | $43.50 | 59.11% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $25.26 | $37.00 | 46.48% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| RNA | Avidity Biosciences | $41.71 | $50.00 | 19.88% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| RYTM | Rhythm Pharmaceuticals | $49.62 | $38.33 | -22.75% | Buy |
RYTM Forecast FAQ
Is Rhythm Pharmaceuticals a good buy?
Yes, according to 5 Wall Street analysts, Rhythm Pharmaceuticals (RYTM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of RYTM's total ratings.
What is RYTM's price target?
Rhythm Pharmaceuticals (RYTM) average price target is $38.33 with a range of $25 to $55, implying a -22.75% from its last price of $49.62. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Rhythm Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for RYTM stock, the company can go down by -22.75% (from the last price of $49.62 to the average price target of $38.33), up by 10.84% based on the highest stock price target, and down by -49.62% based on the lowest stock price target.
Can Rhythm Pharmaceuticals stock reach $70?
RYTM's average twelve months analyst stock price target of $38.33 does not support the claim that Rhythm Pharmaceuticals can reach $70 in the near future.
What are Rhythm Pharmaceuticals's analysts' financial forecasts?
Rhythm Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $123.48M (high $128.59M, low $115.77M), average EBITDA is $-24.697M (high $-23.154M, low $-25.718M), average net income is $-284M (high $-251M, low $-322M), average SG&A $719.31M (high $749.04M, low $674.38M), and average EPS is $-4.658 (high $-4.114, low $-5.284). RYTM's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $167.19M (high $173.97M, low $157.09M), average EBITDA is $-33.437M (high $-31.418M, low $-34.794M), average net income is $-204M (high $-188M, low $-215M), average SG&A $973.87M (high $1.01B, low $915.06M), and average EPS is $-3.35 (high $-3.087, low $-3.527).
Did the RYTM's actual financial results beat the analysts' financial forecasts?
Based on Rhythm Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $77.43M, beating the average analysts forecast of $74.71M by 3.64%. Apple's EBITDA was $-184M, beating the average prediction of $-14.941M by 1133.89%. The company's net income was $-185M, beating the average estimation of $-181M by 2.23%. Apple's SG&A was $117.53M, missing the average forecast of $435.16M by -72.99%. Lastly, the company's EPS was $-0.0032, missing the average prediction of $-2.961 by -99.89%. In terms of the last quarterly report (Sep 2023), Rhythm Pharmaceuticals's revenue was $22.5M, beating the average analysts' forecast of $22.18M by 1.47%. The company's EBITDA was $-40.646M, beating the average prediction of $-4.436M by 816.36%. Rhythm Pharmaceuticals's net income was $-44.163M, missing the average estimation of $-45.149M by -2.18%. The company's SG&A was $30.48M, missing the average forecast of $129.19M by -76.41%. Lastly, the company's EPS was $-0.76, beating the average prediction of $-0.74 by 2.70%